Form 4: Axsome Director Coleman Executes Stock Sales

Director Mark Coleman sold 17,537 shares of Axsome Therapeutics common stock via a pre-arranged 10b5-1 trading plan.

Summary

• Director Mark Coleman sold a total of 17,537 shares of Axsome Therapeutics (AXSM) common stock.
• The sales occurred across three dates: May 29, 2026, June 1, 2026, and June 2, 2026.
• The transactions were executed pursuant to a pre-approved Rule 10b5-1 trading plan.
• Following these transactions, the director retains direct ownership of 29,603 shares and indirect ownership of 403,856 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were pre-planned and represent a standard liquidity event for an insider.

Positives

• The sales were conducted under a pre-planned 10b5-1 program, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The sale of 17,537 shares represents a reduction in the director's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in the short-term share price performance, although these sales were pre-planned.

Future Outlook

No forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The transactions were executed pursuant to a pre-approved 10b5-1 plan.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine practice for corporate executives and directors in the biotechnology sector to manage personal liquidity and diversify portfolios.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for biotech executives to avoid potential insider trading allegations.
• The volume of shares sold is relatively small compared to the director's total holdings, which is consistent with standard wealth management practices.

Stakeholder Impact

• Shareholders should note the reduction in direct insider ownership, though the pre-planned nature of the sale mitigates negative sentiment.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Insider Trading, Form 4, Director Sale, 10b5-1